BRAF and melanoma: Targeting the MAP kinase pathway in patients with advanced melanoma was first attempted with sorafenib, either alone or in combination with chemotherapy with ultimately disappointing results 8, 9, 10, making it clear that more selective inhibitors of BRAF were needed.